NASDAQ
No price data available for this timeframe.
Recursion Pharmaceuticals, Inc. (RXRX) has had 34 insider transactions recently, with net insider activity of +$1.82M (net buying). The most active insider is Khan Najat (Director, officer: ceo and president).
Total Transactions
34
13 buys /21 sells
Shares Acquired
2,917,041
Transactions: 13•Avg: 224,387.77
Shares Disposed
1,092,315
Transactions: 21•Avg: 52,015
Net Activity
+1,824,726
Net Selling•Ratio: 61.9%
Q1 2026(Current) | 2,917,041 | 1,092,315 | +1,824,726 | 61.90% |
Q4 2025 | 679,678 | 1,284,996 | -605,318 | 43.48% |
Q3 2025 | 866,414 | 1,709,459 | -843,045 | 44.44% |
Q2 2025 | 401,296 | 85,529 | +315,767 | 320.00% |
Q1 2025 | 2,634,608 | 428,508 | +2,206,100 | 100.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q1 2026
Acquired vs Disposed Shares
Net Accumulation: 1,824,726 shares•Acquired/Disposed Ratio: 61.9%
Net Activity | |||||
|---|---|---|---|---|---|
KN Khan Najat | Director, officer: ceo and president | 10 | 1,958,668 | 207,019 | +1,751,649 |
GC Gibson Christopher | Director | 58 | 1,491,887 | 2,928,125 | -1,436,238 |
BB Borgeson Blake | Director | 5 | 22,016 | 830,000 | -807,984 |
HD Hallett David | Officer: chief scientific officer | 10 | 526,318 | 984,919 | -458,601 |
TBR Taylor Ben R | Officer: chief financial officer | 11 | 470,533 | 98,318 | +372,215 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2026-03-03 | Director | Sale | 170,000 | $3.46 | $588,200 | 6,259,863 | |
2026-02-17 | Officer: chief scientific officer | Sale | 11,908 | $3.49 | $41,558.92 | 1,097,151 | |
2026-02-19 | Director | Sale | 40,000 | $0 | $0 | 4,543,334 | |
2026-02-19 | Director | Purchase | 40,000 | $0 | $0 | 946,556 | |
2026-02-19 | Director | Sale | 40,000 | $3.46 | $138,400 | 906,556 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
BB Borgeson Blake | Director | Mar 4, 2026 | |
HD Hallett David | Officer: chief scientific officer | Feb 19, 2026 | |
GC Gibson Christopher | Director | Feb 19, 2026 | |
GC Gibson Christopher | Director | Feb 19, 2026 | |
GC Gibson Christopher | Director | Feb 19, 2026 |
Net change in shares shown on right